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To the Editor—Growing evidence supports the positive impact of
antimicrobial stewardship programs (ASPs) on antimicrobial use,
including pediatrics.1 Although short of the level of acceptance
these have reached in the United States, the implementation of
pediatric ASPs in European hospitals has increased over the last
few years.1
It has been suggested that the ASP should be helpful in the
preparation for and response to the SARS-CoV-2/COVID-19 out-
break,2 but no formal recommendations have been published.
Whether pediatric ASP remains an essential activity or not during
the COVID-19 pandemic has yet to be clarified. Here, we describe
how the COVID-19 pandemic has impacted antimicrobial use in a
referral pediatric hospital, and we propose a supporting role for
ASP teams in the local management of the outbreak.
The first COVID-19 case in Catalonia, Spain, was reported on
February 25, 2020. By mid-March, most pediatric and obstetrics
departments in the region were shut to increase the capacity for
adult COVID-19 patients. Hospital Sant Joan de Déu Barcelona
(SJD) remained the largest pediatric and maternal referral center
in the region. COVID-19 and non–COVID-19 pediatric and
young adult patients were transferred to our wards and pediatric
ICU (PICU), and the number of daily deliveries tripled, whereas
all nonemergency clinical, teaching, and research activities were
postponed. Compared to the same months in 2019, in March
2020, total hospital stays decreased by 0.8% in the PICU and
15.2% in non-PICU areas, and in April 2020, total hospital stays
decreased by 23.7% in the PICU and 22.2% in non-PICU areas.
Following institutional recommendations, the SJD-ASP3 team
reduced on-site work, but they continued to provide specific
recommendations on individual antimicrobial prescriptions upon
consultation by prescribers, and they monitored systemic antibi-
otic and antifungal use: days of-therapy (DOT) per 100 days
present (DP). From March 16 to April 30 2020, 210 randomly
selected prescriptions were assessed for quality.3
Because SARS-CoV-2 is a viral infection, it is not expected to
directly influence antibiotic or antifungal use beyond the use of
antibiotics with possible antiviral effect (ie, azithromycin)4 and
the use of broad-spectrum antibiotics for superinfection in severe
COVID-19 patients.5 However, we also observed antimicrobial use
changes indirectly related to the outbreak. Antimicrobial use in
March and April 2020 was significantly higher than in the same
months in 2019 (Table 1). As expected, the use of azithromycin,
included as first-line therapy in severe COVID-19 patients in
combination with hydroxychloroquine, increased, particularly in
the PICU. The use of ceftriaxone and teicoplanin, which were also
prescribed at admission in severe COVID-19 cases, doubled in
the PICU in April 2020 compared with April 2019. Other than
ceftriaxone, antibiotics for community-acquired infections were
prescribed less than in the same period in 2019, and cefazolin
use decreased due to the dramatic drop in the number of surgeries.
In contrast, the use of most broad-spectrum anti–gram-negative
drugs with anti-Pseudomonas activity rose in the PICU, and
piperacillin-tazobactam and ciprofloxacin use also increased in
non-PICU patients. These changes were probably related to the
transfer of patients with immunosuppressive and/or other com-
plex conditions from other centers that had shut their pediatric
departments. Similarly, the rise in micafungin use and, to a lesser
extent, voriconazole use, was likely related to the transfer of
oncological and hematopoietic stem cell transplantation (HSCT)
patients already on antifungal prophylaxis or antifungal treatment
in accordance with other institutions’ local protocols. The tempo-
rary modification of our antifungal prophylaxis protocol for
oncology patients (inhaled liposomal amphotericin plus oral fluco-
nazole) meant minimizing the use of nebulized drugs and led to an
increase in intravenous liposomal amphotericin use.
Despitemajor changes in antimicrobial use, we have not observed
a critical deterioration of antimicrobial prescription quality to date.
Of the 210 evaluated prescriptions, 167 (79.5%) were considered
‘optimal’ in accordance with current protocols, compared with
316 of 400 (79.0%) in the same period in 2019. However, continuous
monitoring allowed the identification of high workload areas deserv-
ing enhanced support, like involving the care of oncology patients.
In the context of a pandemic, changing clinical circumstances
may negatively affect the quality of antimicrobial prescriptions;
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Table 1. Total Antimicrobial Use (AU) and Selected Antibiotic (Ab) and Antifungal (Af) Use in February, March, and April 2019 and 2020, in Days of Therapy (DOT) per
100 Days Present (DP) in PICU and Non-PICU Areas (Excluding Operating Rooms)a
February (DOT/100 DP) March (DOT/100 DP) April (DOT/100 DP)
Year Non-PICU PICU Total Non-PICU PICU Total Non-PICU PICU Total
AU (AbþAf) 2019 62.9 109.2 172.1 63.3 91.9 155.2 63.3 82.8 146.0
2020 −0.4 −10.0 −10.4 þ6.6 þ6.6 þ13.2 −1.4 þ56.9 þ55.5
Total Antibiotics 2019 57.4 103.5 160.9 57.4 89.6 147.0 57.2 79.5 136.7
2020 −0.8 −9.9 −10.7 þ4.5 −2.9 þ1.6 −2.0 þ37.5 þ35.5
Total Antifungals 2019 5.5 5.7 11.2 5.9 2.3 8.2 6.1 3.2 9.3
2020 þ0.5 −0.2 þ0.3 þ2.1 þ9.5 þ11.6 þ0.6 þ19.4 þ19.9
Selected Antibiotics
Amikacin 2019 1.1 6.1 7.2 0.4 1.5 1.9 0.7 0.5 1.2
2020 −0.3 −4.6 −4.9 þ0.8 −0.7 þ0.1 þ0.2 þ0.8 þ1.0
Amoxicillin 2019 3.8 2.6 6.4 3.4 4.6 8.0 4.3 0.5 4.8
2020 þ0.7 −1.0 −0.3 þ0.6 −1.1 −0.5 −2.1 þ5.3 þ3.2
Amoxicillin/clavulanate 2019 11.2 12.9 24.0 12.7 9.6 22.3 12.7 8.5 21.2
2020 −0.9 þ0.4 −0.6 −2.0 −2.1 −4.1 −5.4 −2.3 −7.7
Ampicillin 2019 5.2 1.3 6.5 4.2 5.1 9.3 3.6 1.4 5.0
2020 −1.9 þ0.8 −1.1 −0.7 −2.6 −3.3 −1.4 þ0.2 −1.2
Azithromycin 2019 1.5 3.3 4.8 2.1 4.8 6.9 2.2 6.0 8.1
2020 þ0.2 þ1.2 þ1.4 þ0.9 þ4.2 þ5.1 þ0.4 þ4.1 þ4.5
Cefazolin 2019 1.4 17.9 19.2 1.9 15.8 17.8 2.1 15.7 17.8
2020 þ1.4 −4.4 −3.0 þ0.3 −2.5 −2.2 −1.1 −2.5 −3.6
Cefotaxime 2019 2.3 12.4 14.7 2.8 6.8 9.6 1.3 9.7 11.0
2020 −0.8 −4.1 −4.9 −1.0 −2.4 −3.4 þ0.6 −3.5 −2.9
Ceftazidime 2019 0.7 5.0 5.7 0.6 0.8 1.4 0.2 0.9 1.1
2020 þ0.1 −4.7 −4.7 þ0.2 0 þ0.2 þ0.3 −0.9 −0.6
Ceftriaxone 2019 5.2 1.7 7.0 5.4 2.6 8.1 5.8 1.4 7.1
2020 −1.3 þ1.7 þ0.4 0 þ0.2 þ0.2 þ0.1 þ1.8 þ1.8
Ciprofloxacin 2019 1.2 3.1 4.2 1.3 4.5 5.7 1.5 6.8 8.3
2020 þ0.2 þ1.7 þ1.9 þ0.6 −2.0 −1.4 þ1.3 þ0.3 þ1.7
Linezolid 2019 0.1 3.1 3.1 0.2 2.3 2.5 0.3 1.0 1.3
2020 þ0.3 þ0.7 þ1.0 −0.1 −2.1 −2.3 −0.2 −0.1 −0.4
Meropenem 2019 5.0 3.7 8.7 4.0 2.8 6.8 5.1 4.6 9.7
2020 −2.2 −1.2 −3.4 −0.9 þ0.9 −0.1 −1.9 þ4.8 þ2.9
Piperacillin/tazobactam 2019 2.3 6.8 9.0 1.2 10.7 12.0 1.9 4.9 6.9
2020 þ1.4 þ0.7 þ2.0 þ3.2 þ2.9 þ6.2 þ2.6 þ12.3 þ14.9
Teicoplanin 2019 0.1 0.4 0.5 0.2 1.0 1.2 0.2 1.2 1.4
2020 þ0.7 þ0.6 þ1.3 þ0.7 þ2.0 2.7 þ0.2 þ7.1 þ7.3
Vancomycin 2019 3.8 15.0 18.8 3.1 10.9 14.0 3.3 7.2 10.5
2020 þ0.3 −2.0 −1.7 þ2.4 −1.4 þ1.0 þ0.7 þ0.9 þ1.5
Selected Antifungals
Fluconazole 2019 1.6 0.7 2.2 0 2.3 2.3 2.6 3.2 5.8
2020 þ1.9 −0.4 þ1.5 þ2.7 −1.6 þ1.1 −2.4 −3.2 −5.7
Liposomal amphotericin 2019 1.6 0.4 2.0 1.7 0 1.7 1.5 0 1.5
2020 −0.7 þ1.0 þ0.4 þ1.5 þ1.0 þ2.5 þ1.8 þ1.6 þ3.4
Micafungin 2019 0.6 3.9 4.6 0 0 0 0 0 0
2020 þ0.1 −0.7 −0.6 þ0.1 þ7.0 þ7.1 þ0.3 þ13.2 þ13.5
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prescribers have to work outside their comfort zone, dealing with a
new disease6 and/or ‘unusual’ patient profiles (ie, young adults or
pregnant women in a PICU in our case). NewCOVID-19 protocols
are constantly updated in accordance with newly available infor-
mation, and previous protocols have been temporarily modified
in favor of medical nonsurgical management of some conditions
(eg, noncomplicated appendicitis).7
Our data show that the SARS-CoV-2 pandemic has the potential
to have a significant impact on antimicrobial use in the pediatric
inpatient population; pediatric ASP monitoring and interventions
remain useful to preserve the quality of prescriptions, at least in
the short term. However, the COVID-19 pandemic is still ongoing,
as are other non–COVID-19 health issues such as AMR,5 so health-
care resource distribution and organization in the post–COVID-19
period are uncertain. Planning the response to epidemic waves
should include the widespread integration of ASP, with (1) involve-
ment of the ASP team in guidelines development as exemplified in
“Multicenter Initial Guidance on Use of Antivirals for Children with
COVID-19/SARS-CoV-2”8; (2) integrated response of commonASP
local and external partnerships and infrastructures, including struc-
tured interviews, formularies, and other information technology
tools9; and (3) coordination of indicator selection and monitoring
routines to support a continuous evaluation strategy.
If pediatric ASPs have suffered some weakening in the current
crisis, they should be reinforced promptly to sustain high-quality
care, maintaining the principles of antibiotic stewardship.5 The
potential benefit of a more active role for pediatric ASPs in the out-
break response, above and beyond their regular activities, should
be taken into consideration.
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Table 1. (Continued )
February (DOT/100 DP) March (DOT/100 DP) April (DOT/100 DP)
Year Non-PICU PICU Total Non-PICU PICU Total Non-PICU PICU Total
Posaconazole 2019 1.0 0 1.0 0.3 0 0.3 1.2 0 1.2
2020 −0.5 þ0.4 0 þ1.2 þ0.3 þ1.5 þ1.0 þ0.7 þ1.6
Voriconazole 2019 0.7 0.7 1.4 1.4 0 1.4 0.4 0 0.4
2020 −0.3 −0.7 −1.0 −1.0 þ2.8 þ1.8 þ0.2 þ7.2 þ7.3
Note. Ab, antibiotic; Af, antifungal; AU, antimicrobial use; DOT, days of therapy; DP, days present; PICU, pediatric intensive care unit.
aYear 2020 data are given as increases or decreases compared to the same month in year 2019.
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